Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FLORHAM PARK, N.J., AUG. 07, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED BUSINESS UPDATES.

PHATHOM PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

FLORHAM PARK, N.J., JULY 28, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE WEBCAST AT 8:00 AM EDT ON THURSDAY, AUGUST 7, 2025, TO REPORT ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE.

PHATHOM PHARMACEUTICALS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON THURSDAY, AUGUST 7, 2025

FLORHAM PARK, N.J., JUNE 23, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THAT, IN CONNECTION WITH THE APPOINTMENT OF ANNE MARIE COOK AS CHIEF LEGAL OFFICER AND CORPORATE SECRETARY, THE COMPANY'S BOARD OF DIRECTORS HAS APPROVED THE GRANT OF INDUCEMENT AWARDS.

PHATHOM PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

FLORHAM PARK, N.J., JUNE 23, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF ANNE MARIE COOK, J.D.

PHATHOM PHARMACEUTICALS APPOINTS ANNE MARIE COOK AS CHIEF LEGAL OFFICER AND CORPORATE SECRETARY

FLORHAM PARK, N.J., JUNE 16, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS UPDATED THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS (THE ORANGE BOOK) TO ACCURATELY REFLECT THE FULL 10-YEAR PERIOD OF NON-PATENT NEW CHEMICAL ENTITY (NCE) EXCLUSIVITY FOR VOQUEZNA (VONOPRAZAN) 10 MG AND 20 MG TABLETS.

PHATHOM PHARMACEUTICALS ANNOUNCES FDA CORRECTION TO ORANGE BOOK LISTING, CONFIRMING 10 YEARS OF REGULATORY EXCLUSIVITY FOR VOQUEZNA (VONOPRAZAN) TABLETS THROUGH MAY 3, 2032

FLORHAM PARK, N.J., JUNE 06, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED PHATHOM'S CITIZEN PETITION FILED ON DECEMBER 11, 2024 AND COMMUNICATED THE AGENCY'S INTENTION TO CORRECT THE ORANGE BOOK TO RECOGNIZE THE PROPER 10 YEARS OF NEW CHEMICAL ENTITY EXCLUSIVITY FOR VOQUEZNA (VONOPRAZAN) TABLETS, EXTENDING THROUGH MAY 3, 2032.

PHATHOM PHARMACEUTICALS ANNOUNCES POSITIVE FDA DECISION TO RECOGNIZE 10 YEARS OF REGULATORY EXCLUSIVITY FOR VOQUEZNA (VONOPRAZAN) TABLETS THROUGH MAY 3, 2032

FLORHAM PARK, N.J., MAY 15, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, ANNOUNCED TODAY THAT THE COMPANY IS SCHEDULED TO PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN MAY AND JUNE: H.C.

PHATHOM PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

FLORHAM PARK, N.J., MAY 01, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THAT, IN CONNECTION WITH THE APPOINTMENT OF JONATHAN BENTLEY AS SENIOR VICE PRESIDENT, HEAD OF SALES, THE COMPANY'S BOARD OF DIRECTORS HAS APPROVED THE GRANT OF INDUCEMENT AWARDS.

VOQUEZNA LAUNCH MOMENTUM CONTINUES WITH OVER 390,000 PRESCRIPTIONS FILLED TO DATE, WRITTEN BY MORE THAN 23,600 HEALTHCARE PROVIDERS NET REVENUES OF $28.5 MILLION REPORTED FOR Q1 FILLED VOQUEZNA PRESCRIPTIONS INCREASED ~8% IN Q1 OVER THE PRIOR QUARTER DESPITE SEASONAL HEADWINDS STRATEGIC COST REDUCTIONS AND EXECUTIVE LEADERSHIP CHANGES IMPLEMENTED TO SUPPORT SUSTAINABLE REVENUE GROWTH AND ACHIEVE PROFIT FROM OPERATIONS, EXCLUDING STOCK-BASED COMPENSATION, IN 2026 MANAGEMENT TO HOST CONFERENCE CALL TODAY, MAY 1, 2025, AT 8:00 A.M. ET FLORHAM PARK, N.J.

PHATHOM PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

FLORHAM PARK, N.J., APRIL 28, 2025 (GLOBE NEWSWIRE) -- PHATHOM PHARMACEUTICALS, INC. (NASDAQ: PHAT), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR GASTROINTESTINAL (GI) DISEASES, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT REAL-WORLD DATA FOR ITS FIRST-IN-CLASS TREATMENT VOQUEZNA (VONOPRAZAN)AT DIGESTIVE DISEASE WEEK (DDW) BEING HELD MAY 36, 2025, IN SAN DIEGO, CA. VOQUEZNA IS THE FIRST AND ONLY TREATMENT OF ITS KIND APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR USE IN ADULTS FOR THE RELIEF OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GERD AND FOR THE TREATMENT OF ALL SEVERITIES OF EROSIVE ESOPHAGITIS (EE), COMMONLY REFERRED TO AS EROSIVE GERD, AND RELIEF OF RELATED HEARTBURN.

Phathom Pharmaceuticals, Inc.

PHAT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Phathom Pharmaceuticals, Inc.

PHAT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PHAT